Physician profile
Christopher Carson
NPI 1235717802
$1,826.21
in general payments reported to CMS, 2019-2025
11 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $41.36 · 2024: $434 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $474.18 | 2024-2025 | Tavneos, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $341.28 | 2024-2025 | Saphnelo |
| Abbvie INC. | $252.90 | 2025 | |
| Janssen Biotech, INC. | $186.01 | 2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $180.84 | 2025 | |
| US Oncology Corporate, INC. | $167.54 | 2024 | |
| Glaxosmithkline, LLC. | $117.31 | 2025 | Benlysta |
| Ucb, INC. | $50.33 | 2025 | Bimzelx |
| Incyte Corporation | $22.60 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.76 | 2023 | Spevigo |
| Tonix Medicines, INC. | $14.46 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.